1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19222
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchellens, J. H.en
dc.contributor.authorDombernowsky, P.en
dc.contributor.authorCassidy, J.en
dc.contributor.authorEpelbaum, R.en
dc.contributor.authorDirix, L.en
dc.contributor.authorCox, E. H.en
dc.contributor.authorWanders, J.en
dc.contributor.authorCalabresi, F.en
dc.contributor.authorParidaens, R.en
dc.contributor.authorMonfardini, S.en
dc.contributor.authorWolff, J.en
dc.contributor.authorLoos, W. J.en
dc.contributor.authorVerweij, J.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorHanauske, A. R.en
dc.date.accessioned2015-11-24T18:57:55Z-
dc.date.available2015-11-24T18:57:55Z-
dc.identifier.issn0959-4973-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19222-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Agents/*pharmacokineticsen
dc.subjectArea Under Curveen
dc.subjectAziridines/*pharmacokineticsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subject*Indolequinonesen
dc.subjectIndoles/*pharmacokineticsen
dc.subjectMaleen
dc.subjectMetabolic Clearance Rateen
dc.subjectMiddle Ageden
dc.subjectNeoplasms/drug therapy/*metabolismen
dc.subjectPopulation Dynamicsen
dc.subjectProspective Studiesen
dc.subjectSampling Studiesen
dc.titlePopulation pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9en
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11487714-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2001-
heal.abstractPopulation pharmacokinetic-dynamic analysis was prospectively integrated in the clinical phase II programme of EO9 to determine the population pharmacokinetic profile in a larger population of patients, to estimate individual patient pharmacokinetic parameters, and to investigate relationships between drug exposure and clinical outcome. A sparse sampling method was developed, which involved three sampling times, and was implemented during course 1. A Bayesian algorithm was used to estimate individual pharmacokinetic parameters, in particular total plasma clearance (CL) of EO9 and area under the curve (AUC). In total, samples were collected of 85 (65%) of the patients. Pharmacokinetic evaluation was successful in 61 (72%) of the sampled patients. CL of EO9 showed substantial variability (median 5.08 l/min; range 2.67-6.42) and was of the same magnitude as in the phase I study where full pharmacokinetic profiles were used. No significant relationships were noticed between exposure parameters and safety, but overall limited toxicity was observed. No tumor responses were documented. Prospective implementation of large-scale population pharmacokinetic-dynamic analysis is feasible and may generate important findings, in particular when tumor responses and relevant toxicity are observed.en
heal.journalNameAnticancer Drugsen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons